Search company, investor...

Stage

Other Investors | Alive

About Kaperio

Kaperio is a biopharmaceutical company focused on cardiovascular disease.

Headquarters Location

St. Louis, Missouri, 63101,

United States

Loading...

Loading...

Kaperio Frequently Asked Questions (FAQ)

  • Where is Kaperio's headquarters?

    Kaperio's headquarters is located at St. Louis.

  • What is Kaperio's latest funding round?

    Kaperio's latest funding round is Other Investors.

  • Who are the investors of Kaperio?

    Investors of Kaperio include RiverVest Venture Partners.

  • Who are Kaperio's competitors?

    Competitors of Kaperio include Portola Pharmaceuticals, Cardioxyl Pharmaceuticals, Zevra Therapeutics, Trophos, EGEN and 7 more.

Loading...

Compare Kaperio to Competitors

Oligomerix Logo
Oligomerix

Oligomerix is a biotechnology company that focuses on the development of disease-modifying therapeutics for neurodegenerative diseases, specifically those characterized by aberrant tau protein. The company's main offerings include small molecule inhibitors that target the tau aggregation cascade and its progression, aiming to treat conditions ranging from rare tauopathies to Alzheimer's disease. The company primarily serves the healthcare sector, particularly in the area of neurodegenerative diseases. It was founded in 2006 and is based in West Harrison, New York.

B
Bikam Pharmaceuticals

Bikam Pharmaceuticals is a biopharmaceutical company. It focuses on the discovery and development of small-molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. It was founded in 2007 and is based in Cambridge, Massachusetts.

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biopharmaceutical company that operates in the healthcare sector. The company focuses on the development of medicines using ribonucleic acid interference (RNAi) technology to silence or turn off the genes that cause or contribute to diseases. These therapies are aimed at both rare and common diseases. It was founded in 2007 and is based in Watertown, Massachusetts.

I
Inflazyme Pharmaceuticals

Juli4D is an online lottery platform specializing in providing access to major Asian lottery markets, particularly in the online gambling industry. The company offers services that allow users to bet on lottery numbers, track lottery results, and manage their gambling accounts. Juli4D is recognized for its partnerships with Toto SGP and Toto HK, offering a trusted platform for lottery enthusiasts. It was founded in 1992 and is based in Richmond, British Columbia.

H
Hunter-Fleming

Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.

N
Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.